Biotech | February 24, 2022
Aadi Bioscience launches Fyarro in the USA
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Previously, the use of the drug was limited to patients requiring hospitalization
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Subscribe To Our Newsletter & Stay Updated
